摘要
目的评价三氧化二砷联合经导管动脉化疗栓塞术(TACE)治疗晚期原发性肝癌的有效性和安全性。方法 25例晚期原发性肝癌患者给予三氧化二砷联合TACE治疗,并观察疾病控制率、疾病进展时间、生存时间及不良反应。结果全组25例患者中,完全缓解0例,部分缓解4例,稳定14例,进展7例,有效率为16.0%,疾病控制率为72.0%。中位疾病进展时间为2.2(95%CI:1.3~3.1)个月;中位生存时间6.0(95%CI:5.0~7.0)个月。结论三氧化二砷联合TACE治疗晚期原发性肝癌疗效肯定,不良反应可耐受。
Objective To assess the efficacy and toxicities of arsenic trioxide combined with transcatheter arterial chemoembolization(TACE) in the treatment of primary hepatocellular carcinoma.Methods A total of 25 patients with primary hepatocellular carcinoma were treated with arsenic trioxide combined with TACE,and the disease control rate,time to progress,overall survival and safety were investigated.Results The response rate and the disease control rate in the 25 patients were 16.0% and 72.0%,including 4 patients with partial response,14 patients with stable disease and 7 patients with progressive disease.The median time to progress and the overall survival time were2.2(95% CI:1.3-3.1) months and 6.0(95% CI:5.0-7.0) months.Conclusion Arsenic trioxide combined with TACE has good curative effect in the treatment of primary hepatocellular carcinoma,and the toxicities could be tolerated.
出处
《肿瘤基础与临床》
2017年第5期398-400,共3页
journal of basic and clinical oncology
关键词
原发性肝癌
三氧化二砷
经导管动脉化疗栓塞术
primary hepatocellular carcinoma
arsenic trioxide
transcatheter arterial chemoembolization
